

The logo for the American Society of Transplantation (AST) features the letters "AST" in a bold, white, sans-serif font.

AMERICAN SOCIETY OF
TRANSPLANTATION

The CEOT logo consists of the letters "CEOT" in a white, sans-serif font, enclosed within a circular arrangement of black dots of varying sizes.

CEOT

CUTTING EDGE of TRANSPLANTATION

TRANSPLANT SUMMIT 2018

*Breaking Through
Regulatory Barriers to
Unleash Transplant
Innovation*

FEBRUARY 8-10, 2018
Arizona Biltmore
Phoenix, AZ

NAME: _____

For more information, visit www.myAST.org/meetings

How can Veloxis Transplant Support help my patients?

Veloxis Transplant Support can help provide access to medications for your patients, regardless of their circumstances. Available support includes a free 30-day starter pack, \$0 Co-pay*, and Patient Assistance Program**.

Wow! My patients can definitely benefit from a co-pay card. How can I receive assistance?

Simply by calling Veloxis Transplant Support at 1-844-VELOXIS or by speaking with your local Veloxis Transplant Account Manager.

Eligibility Requirements

* Eligible insured patients can save up to a maximum benefit of \$5,000 annually off the patient's co-pay or out-of-pocket expenses of ENVARSUS XR. Patient is responsible for any differential over \$5,000. This offer can be used an unlimited number of times. Offer not valid for cash-paying patients or where drug is not covered by the primary insurance. This offer is valid in the United States. No substitutions permitted. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (such as medical assistance programs).

** Patient Eligibility for Free Trial Offer: This voucher is good for patients according to the following eligibility criteria and Terms of Use below. No claim for reimbursement for product dispensed pursuant to this voucher may be submitted to ANY third-party payer, whether a commercial, private, or a government payer. This offer is not insurance and is not valid for mail order. Quantity limits may apply. Terms of Use: This voucher may be redeemed with an accompanying prescription for a 30-day free trial of a Veloxis medication. No substitutions permitted. This voucher is good for the purchase of a Veloxis medication and lawfully purchased from an authorized retailer or distributor in the United States. Offer not valid where prohibited by law, taxed, or restricted. Offer is not transferable, is limited to one per person, and may not be combined with any other offer. Voucher must be presented along with a valid prescription at the time of purchase. This offer may be changed or discontinued at any time without notice by Veloxis. Offer expires 12/31/2017. For questions, please call 1-844-728-3479. This is not a discount or rebate, and is not conditioned upon any past, present, or future purchase.

GENERAL INFORMATION

REGISTRATION DESK

| | |
|----------|--------------------|
| Thursday | 11:00 AM – 7:00 PM |
| Friday | 7:00 AM – 4:00 PM |
| Saturday | 7:00 AM – 4:00 PM |

EXHIBIT HALL (POSTERS AND INDUSTRY DISPLAYS)

| | |
|----------|--------------------|
| Thursday | 4:00 PM – 7:00 PM |
| Friday | 10:00 AM – 4:00 PM |
| Saturday | 10:00 AM – 4:00 PM |

INDUSTRY DISPLAYS

Be sure to visit the following companies in the exhibit hall during breaks and reception:

Astellas Pharma

CareDx

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Veloxis Pharmaceuticals

VitaerisBio

EVENING EVENTS

Welcome Reception and Posters

Thursday 5:45 PM – 7:00 PM

Join your colleagues for a warm welcome to the Cutting Edge of Transplantation (CEoT) meeting. View the posters, visit the exhibit booths, and enjoy ample food and drinks with AST.

Poolside Reception, Paradise Pool

Saturday 5:00 PM – 7:00 PM

Conclude your CEoT experience by winding down Poolside with your colleagues.

WIFI

Network Name: AZB Meetings

Password: ast2018

MEALS


Breakfast and lunch will be provided by AST Friday and Saturday in the FLW Ballroom. Break refreshments will be provided and served in the Exhibit Hall. Please refer to program agenda for time details. Please visit the hotel concierge or the AST registration desk for dining suggestions.

NAME BADGE

All attendees must wear the AST-provided name badge always to gain access to CEoT events and sessions.

GUESTS

All guests must be registered and wear their name badge to access the evening reception on Thursday. All other sessions and events are educational in nature and we request that guests do not attend.



PROGRAM PLANNING COMMITTEE

Anil Chandraker, MD, FASN, FAST, FRCP

Co-Chair and Board Liaison

Brigham & Women's Hospital

Kenneth A. Newell, MD, PhD, FAST

Co-Chair

Emory University School of Medicine

Andrew B. Adams, MD, PhD

Emory University School of Medicine

Charles Alexander, RN, MSN, MBA, CPTC

The Living Legacy Foundation of Maryland

Roy Bloom, MD

Hospital of the University of Pennsylvania

David P. Foley, MD, FACS

University of Wisconsin

Richard N. Formica, Jr., MD

Yale University School of Medicine

Robert S. Gaston, MD

University of Alabama at Birmingham

John Gill, MD, MS

Providence Health Vancouver, BC

David Goldberg, MD, MSCE

Hospital of the University of Pennsylvania

Jon Kobashigawa, MD

Cedars Sinai Heart Institute

Jesse Schold, PhD, M. Stat, M.Ed.

Cleveland Clinic Foundation

Alexander Wiseman, MD

University of Colorado of Denver HSC

INVITED FACULTY AND MODERATORS

Andrew Adams, MD, PhD

Emory University School of
Medicine

**Charles Alexander, RN, MSN,
MBA, CPTC**

The Living Legacy Foundation of
Maryland

James Allan, MD, MBA, FAST

Massachusetts General Hospital

Francisco Arabia, MD

Cedars Sinai Heart Institute

Abbas Ardehali, MD

UCLA Medical Center

Agnes Azimzadeh, PhD

University of Maryland School of
Medicine

Sangeeta Bhorade, MD

Northwestern Memorial Hospital

Roy Bloom, MD

Hospital of the University of
Pennsylvania

Nicholas Braus, MD

Mayo Clinic

**Anil Chandraker, MD, FASN,
FAST, FRCP**

Brigham & Women's Hospital

Matthew Cooper, MD

Georgetown University

Duane Davis, MD

Florida General Hospital

Jonathan D'Cunha, MD

University of Pittsburgh Medical
Center

Gundeep Dhillon, MD, MS

Stanford University

Thomas Egan, MD, MSc

UNC Chapel Hill

Jean Emond, MD

Columbia University

William Federspiel, PhD

McGowan Institute for
Regenerative Medicine, UPMC

David Foley, MD, FACS

University of Wisconsin School of
Medicine and Public Health

Rhondalyn Ford-McLean, MD

University of Pennsylvania

Richard Formica, MD

Yale University School of Medicine

O.H. Frazier, MD

Texas Heart Institute

Jon Friedman, MD, FAST

Optum Health Complex Medical
Conditions

Robert Gaston, MD

University of Alabama at
Birmingham

John Gill, MD, MS

Providence Health

Alexandra Glazier, JD, MPH

New England Donor Services

David Goldberg, MD, MSCE

University of Pennsylvania

Melissa Greenwald, MD

Health Resources and Services
Administration

Shelley Hall, MD

Baylor University Medical Center

**Congresswoman Jaime
Herrera Beutler, (R-WA)****Charles Hoopes, MD**

University of Alabama

Val Jeevanandum, MD

University of Chicago

Stephen Joel Coons, PhD

Critical Path Institute

Bertram Kasiske, MD

Hennepin County Medical Center

Shaf Keshavjee, MD

University of Toronto

Allan Kirk, MD, PhD

Duke University Medical Center

David Klassen, MD

United Network for Organ Sharing

INVITED FACULTY AND MODERATORS (CONTINUED)

Liviu Klein, MD

University of California, San Francisco

Jon Kobashigawa, MD

Cedars Sinai Heart Institute

Joren Madsen, MD

Massachusetts General Hospital

Darren Malinoski, MD

VA Portland Healthcare System

Simon Maltais, MD

Mayo Clinic

Roslyn Mannon, MD

University of Alabama

Arthur Matas, MD

University of Minnesota

Ulf Meier-Kriesche, MD

Veloxis Pharmaceuticals

David Neujhar, MD

Emory University

**Kenneth Newell, MD, PhD,
FAST**

Emory University School of Medicine

Kevin O'Conner MS, PA

LifeCenter Northwest

Robin Pierson, MD

University of Maryland

Luke Preczewski

Jackson Health System

Axel Rahmel, PhD

Deutsche Stiftung
Organtransplantation

**Jesse Schold, PhD, M. Stat,
M. Ed**

Cleveland Clinic Foundation

Palak Shah, MD

Inova Heart & Vascular Institute

Farooq Sheikh

MedStar Health

Brian Shepard, MBA

United Network for Organ Sharing

Jason Smith, MD

University of Washington

Michael Smith, MD

St. Joseph's Hospital

Rachel Smith, PhD

Cedars Sinai Heart Institute

Jon Snyder, PhD

Scientific Registry of Transplant
Recipients

Mark Stegall, MD

Mayo Clinic

Darren Stewart, MS

United Network for Organ Sharing

**Congressman Eric Swalwell,
(D-CA)****Doris Taylor, MD**

Texas Heart Institute

Joseph Tector, MD, PhD

The Kirklin Clinic of UAB Hospital

Jeffrey Teuteberg, MD

Stanford University School of
Medicine

Nicole Turgeon, MD

Emory University

Christopher Wigfield, MD

Advocate Christ Hospital

Martin Zamora, MD

University of Colorado Health
Sciences Center



Better Surveillance for Better Outcomes
www.allosure.com



The Latest Innovation in Kidney Transplant Surveillance

CareDx, Inc. invites you to a lunch symposium* to learn about:

Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients

Friday, February 9, 2018 in Frank Lloyd Wright Salon EF at 12:15 pm

Moving molecular diagnostics from bench to bedside: Clinical implementation in kidney transplant patients

Peter S. Heeger, M.D., Professor of Medicine, Director of Transplant Research, Icahn School of Medicine at Mount Sinai

Early clinical experience with AlloSure in kidney transplant patients

Matthew Weir, M.D., Professor of Medicine, Director of the Division of Nephrology, University of Maryland School of Medicine

Implementation of AlloSure into clinical practice

Alexander Wiseman, M.D., Professor of Medicine, Medical Director, Renal and Transplant Programs, University of Colorado

Clinical application of donor-derived cfDNA testing for heart transplant surveillance

Jon A. Kobashigawa, M.D., Thomas D. Gordon, Professor of Medicine, and Director of the Heart Transplant Program, Cedars-Sinai Medical Center

*This is not an official function of the CEoT Meeting and is not endorsed by AST

Contact Us: 1-888-255-6627 | customer care@caredx.com



© 2018 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

LK-10427 Revision 1 Effective 2018-01



Molecular Microscope®
Diagnostic System

SATELLITE BREAKFAST SYMPOSIA

FEB
10
- SAT -

The Molecular Microscope®, Launching the Next Generation of Transplant Diagnostics

07:00-08:15

Frank Llyod Wright Salon EF

PRESENTERS

Philip F. Halloran MD, Ph.D

Alberta Transplant Applied Genomics Centre

*The New MMDx Reports; What They Say, What They Mean And
How To Use Them*

Gaurav Gupta, MD

Virginia Commonwealth University

*Applying Molecular Diagnostics In Analyzing Renal Allograft
Biopsies, The Richmond Experience*

Alexandre Loupy, MD, Ph.D

Necker Hospital

*Refining Integrative Diagnostic Standards In Transplantation,
The Paris Experience*

All general sessions take place in Frank Lloyd Wright Salon E-F.

Sessions in the heart track take place in Frank Lloyd Wright Salon A-B.

Sessions in the lung track take place in Frank Lloyd Wright Salon C-D.

All Break Refreshments will be held in the Exhibit Hall.

THURSDAY, FEBRUARY 8, 2018

1:45 PM

Welcome Remarks

Frank Lloyd Wright Salon EF
Anil Chandraker, MD, FASN, FAST, FRCP,
Brigham and Women's Hospital
Kenneth Newell, MD, PhD, FAST, Emory
University

2:00 - 3:30 PM

Session 1: Xenotransplantation, Are We Finally Ready? A Field, Challenging and Challenged by Regulation*

Moderators: Andrew Adams, MD, PhD
James Allan, MD, MBA, FAST

2:05 PM

We Are Ready for Prime-Time, Invest Today!
Joseph Tector, MD, PhD

2:30 PM

We're Close but We Need to Consider the
Following Issues Before Sinking in Your
Money
Andrew Adams, MD, PhD

2:55 PM

Hold on Here, Your Money Might be
Better Invested Somewhere Else
Allan Kirk, MD, PhD

Panel Discussion

3:45 PM

Break

4:00 - 5:30 PM

Session 2: Defining True Innovation - Lessons from Transplantation's Past*

Moderators: Kenneth Newell, MD, PhD, FAST
Anil Chandraker, MD, FASN, FAST, FRCP

4:05 PM

Innovation in Surgical Technique – Living
Donor Liver Transplantation
Jean Emond, MD

4:20 PM

Innovation in Immunosuppression
Arthur Matas, MD

4:35 PM

Innovation in Organ Donation
Darren Malinoski, MD

4:50 PM

Innovation in Regulatory Framework – the
National Academy of Science Study
Alexandra Glazier, JD, MPH

Panel Discussion

5:45 - 7:00 PM

Poster & Welcome Reception

Frank Lloyd Wright Salon G

FRIDAY, FEBRUARY 9, 2018

8:00 - 8:45 AM

Continental Breakfast

9:00 - 9:45 AM

Congressional Keynote Speaker

The Honorable Congressman Eric Swalwell
(D-CA)
U.S. House of Representatives

9:45 AM

Break

10:00 - 12:00 PM

Session 3:

Select One of Three Sessions

OPTION ONE

OPTN/UNOS Policies and Organ Utilization - Necessary and Beneficial, or Obstacles to Growth & Innovation?*

Frank Lloyd Wright EF
Moderators: Richard Formica, MD

Deceased Donors Starting Living Donor Chains

10:00 AM

The Rationale and Potential Benefit for
Using Deceased Donors to Start KPD
Chains
Nicole Turgeon, MD

10:10 AM

The Legal and Regulatory Issues Posed by
Using Live Donors to Start KPD Chains
David Klassen, MD

10:20 AM

Panel Discussion

New Paradigms for Allocating Organs - When Should Utility Override Equity?

10:30 AM

European Perspective on Expedited
Allocation
Axel Rahmel, PhD

10:40 AM

Novel Ideas for Expedited Allocation
Darren Stewart, MS

10:50 AM

Proposing a New Paradigm -Less Choice,
More Allocation
Jesse Schold, PhD, M. Stat, M.Ed

11:00 AM

Panel Discussion

*Continuing education credit offered. See separate packet.

†No continuing education credit offered.

Re-Envisioning OPTN/UNOS

- 11:20 AM People and Data
Brian Shepard, MBA
- 11:30 AM Changing OPTN/UNOS Implementation
Policies and Practices: Supporting
Innovation in a Structured Environment
Richard Formica, MD
- 11:40 AM HRSA Role as a Force Innovation in
Transplantation
Melissa Greenwald, MD
- 11:50 AM UNOS Labs: Leveraging Behavioral
Science to Improve Organ Allocation
Darren Stewart, MS
- OPTION TWO**
- Heart Track: Rise of the Machines -
Regulatory Considerations in MCS
Therapy***
- Frank Lloyd Wright Salon AB
Moderators: *Liviu Klein, MD*
Rhondalyn Ford-McLean, MD
- 10:00 AM LVADs as Destination Therapy- When Best
Practice Criteria Meets the Real World
Farooq Sheikh, MD
- 10:15 AM The Total Artificial Heart – What Metrics
Should be Met for Standard Use? For
Future Technology?
Francisco Arabia, MD
- 10:30 AM ECMO and Short Term Support -Utilization
Guidelines and Impact of the New Heart
Allocation System
Jeffrey Teuteberg, MD
- 10:45 AM MCS Complications-Understanding Risks
and Rewards in the Context of Appropriate
Use Benchmarks
Liviu Klein, MD
- 11:00 AM DEBATE:

Innovation in MCS Technology is Helped
by Regulation
Palak Shah, MD
- Innovation in MCS Technology is Hindered
by Regulation
O.H. Frazier, MD
- 11:30 AM The Cost of Success vs the Cost of Failure
– Financial Considerations in Advancing
Innovation
Simon Maltais, MD

OPTION THREE

- Lung Track: The Evolution of Lung
Support Devices - Regulatory
Considerations in Lung
Transplantation***
- Frank Lloyd Wright Salon CD
Moderators: *Sangeeta Borhade, MD*
Christopher Wigfield, MD
- 10:00 AM DEBATE:

ECMO as a Bridge to Transplant Should be
Exempt from 1 Year Mortality Outcomes in
Lung Transplant
- Con
Charles Hoopes, MD
- Pro
Duane Davis, MD
- 10:40 AM DEBATE:

Ex Vivo Lung Perfusion is an Essential Tool
for Donor Optimization
- 11:20 AM The Regulatory Imperative – Impact on the
Practice of Lung Transplant
Christopher Wigfield, MD
- 11:35 AM Regulatory Realities – Redefining Benefit of
Lung Transplant in the Current Era
Gundeep Dhillon, MD, MS
- Pro
Shaf Keshavjee, MD
- Con
Thomas Egan, MD, MSc
- 12:15 – 1:30 PM**
- Satellite Symposium presented by
CareDx, Inc †**
- This is not an official function of the CEoT
meeting and is not endorsed by the AST.
- 1:30 – 2:15 PM**
- Congressional Keynote Speaker**
- The Honorable Congresswoman Jaime
Herrera Beutler (R-WA)
U.S. House of Representatives
- 2:15 PM**
- Inaugural AST Innovation Award
Presentation**
- Anil Chandraker, MD, FASN, FAST, FRCP*
This new award was created to showcase
a project or program that exemplifies
the spirit of innovation on which
transplantation was founded. Join us
to honor the recipient, and hear a brief
presentation on the program's successful,
outside-the-box approach that earned it
the first Innovation Award.

*Continuing education credit offered. See separate packet.

†No continuing education credit offered.

2:45 – 4:45 PM

OPTION ONE

Session 5:

Select One of Three Sessions

Program-Specific Reports: Past, Present and Future. Where do we go from here?*

Frank Lloyd Wright EF

Moderators: Jesse Schold, PhD, M. Stat, M. Ed

John Gill, MD, MS

2:50 PM

The Past

Bertram Kasiske, MD

3:05 PM

The Present

Jon Snyder, PhD

3:25 PM

The Future – What Would an Ideal Report Card Look Like?

Melissa Greenwald, MD

Jon Friedman, MD, FAST

Luke Preczewski

Jesse Schold, PhD, M.Stat, M. Ed

Panel Discussion

OPTION TWO

Heart Track: Alternatives to Heart Transplantation - Overcoming Barriers to Success*

Frank Lloyd Wright AB

Moderators: Joren Madsen, MD

Shelley Hall, MD

2:45 PM

DCD Heart Donation – Understanding the Regulatory and Ethical Issues

Val Jeevanandam, MD

3:05 PM

Xenotransplantation – Promise and Pragmatism

Robin Pierson, MD

3:25 PM

Whole Organ Engineering – Science and Sensibility

Doris Taylor, MD

3:45 PM

Stem Cell Therapy – Engineering Process

Rachel Smith, PhD

4:15 PM

Ex Vivo Heart Perfusion – Removing Time and Distance Barriers

Abbas Ardehali, MD

OPTION THREE

Lung Track: Trials, Tribulations and Triumphs in Lung Transplant Innovations

Frank Lloyd Wright CD

Moderators: Martin Zamora, MD

Duane Davis, MD

2:45 PM

Cell Free DNA and Other Immune Monitoring Techniques in Lung Transplantation – Are We There Yet?

David Neujhar, MD

3:05 PM

Controlled Donation After Determination of Circulatory Death (cDCDD) – Improving Yield

Michael Smith, MD

3:25 PM

Xeno Lung Transplantation – The Path Forward

Agnes Azimzadeh, PhD

3:45 PM

Extracorporeal Lung Support – A Bridge Too Far?

Jonathan D'Cunha, MD

4:15 PM

The Artificial Lung – Can it be Realized?

Williams Federspiel, PhD

SATURDAY, FEBRUARY 10, 2018

7:00 – 8:15 AM

Satellite Symposium presented by One Lambda Inc., A Thermo Fischer Scientific Brand †

This is not an official function of the CEOT meeting and is not endorsed by the AST.

8:15 AM

Break

8:30 – 10:00 AM

Session 6:

Select One of Two Sessions

OPTION ONE

Clinical Therapeutics to Improve Patient Outcomes - The Tribulations of Trials in Transplantation*

Frank Lloyd Wright EF

Moderators: Roy Bloom, MD

Roslyn Mannon, MD

8:30 AM

Tracking Transplant Treatment Trials - Where Are We and What are the Barriers

Roy Bloom, MD

9:00 AM

Victims of Success- Do We Still Need Clinical Trials and If So, What are Our Needs?

Robert Gaston, MD

9:30 AM

Can We Get There? Re-Thinking Clinical Trial Design

Jesse Schold, PhD, M.Stat, M.Ed.

9:45 AM

Panel Discussion with Renata Albrecht, MD
Peter Maag, PhD
Kevin Campbell

*Continuing education credit offered. See separate packet.

†No continuing education credit offered.

OPTION TWO

**Case Studies in Thoracic Transplantation
- Integrating Innovation***

Frank Lloyd Wright AB

Moderators: Jon Kobashigawa, MD

Nicholas Braus, MD

8:30 AM

Extended Criteria Heart vs Destination
LVAD

Liviu Klein, MD

8:45 AM

Hep-C Heart and Lung Transplantation
Shelley Hall, MD

Luke Cunningham, MD

9:00 AM

Ex Vivo Lung

Jon D'Cunha, MD

Lara Schaheen, MD

9:15 AM

Ex Vivo Heart

Jason Smith, MD

Christopher Burke, MD

9:30 AM

DCD Lung

Martin Zamora, MD

Nicholas Braus, MD

10:00 AM

Break

10:30 – 12:00 PM

**Session 7: Approaches to Facilitating
the Approval of New Therapeutics in
Transplantation***

Frank Lloyd Wright EF

Moderators: Kenneth Newell, MD, PhD,
FAST

Anil Chandraker, MD, FASN, FAST, FRCP

10:30 AM

Low and Not So Low Hanging Fruit – New
Study Endpoints and Biomarkers

Ulf Meier-Kriesche, MD

10:50 AM

Regulatory Approaches to Facilitating
the Use of Therapies Approved for Other
Indications in Transplantation

Mark Stegall, MD

11:10 AM

PROs – New Opportunities to Measure
Something That Matters to Patients

Stephen Joel Coons, PhD

Panel Discussion

12:15 PM – 1:30 PM

Lunch

Exhibit Hall

1:30 – 3:00 PM

1:30 PM

1:45 PM

2:00 PM

2:15 PM

2:30 PM

3:00 – 3:30 PM

3:30 – 4:00 PM

4:00 – 4:15 PM

5:00 PM

**Session 8: Out of Synch - How
Can Factors That Drive OPO and
Transplant Center Practice be Aligned
to Increase the Number of Patients
Who Receive a Transplant?***

Frank Lloyd Wright EF

Moderators: John Gill, MD, MS

David Foley, MD, FACS

Critique of the Current OPO Performance
Metrics and Proposed Improvements:Characteristics of an Optimal OPO Metric
David Goldberg, MD, MSCE

My Pick for A New OPO Metric

Charles Alexander, RN, MSN, MBA, CPTC

Regulatory and Financial Considerations
That Impact OPO Performance – What
Changes Would Increase Transplantation?
Kevin O'Connor, MS, PARegulatory and Financial Considerations
That Impact Transplant Center Practice
– What Changes Would Increase
Transplantation?

Matthew Cooper, MD

Reaction to the Proposed Solutions
Brian Shepard, MBAPanel Discussion with
Jon Snyder, PhD**Session 9: Summary Heart/Lung Track**

Frank Lloyd Wright AB

Jon Kobashigawa, MD

Sangeeta Bhorade, MD

Session 10: Summary and Next Steps

Frank Lloyd Wright EF

Anil Chandraker, MD, FASN, FAST, FRCP

Kenneth Newell, MD, PhD, FAST

Closing

Frank Lloyd Wright EF

Anil Chandraker, MD, FASN, FAST, FRCP

Kenneth Newell, MD, PhD, FAST

Poolside Reception

Paradise Pool

*Continuing education credit offered. See separate packet.

†No continuing education credit offered.

AST | AMERICAN SOCIETY OF TRANSPLANTATION

The American Society of Transplantation sincerely thanks the following companies and organizations for their generous support of AST and its activities:

AST 2017 SUPPORTERS

GOLD



PATRON



MERCK

Walgreens
Specialty Pharmacy

SILVER



Russell A. Lagasse Trust

SANOFI GENZYME

FRIEND



Canadian Blood Services
it's in you to give



ENCOMPASS^{RX}
Leaders in Chronic
Disease Management



BRONZE



Bristol-Myers Squibb

Genentech

A Member of the Roche Group



ONE LAMBDA

A Thermo Fisher Scientific Brand

Shire



**Wood MacMillan
Charitable Fund**

AST 2018 CORPORATE AFFILIATES

at time of printing



MERCK



NOVARTIS



ONE LAMBDA
A Thermo Fisher Scientific Brand

SANOFI GENZYME

Shire





You have the power to save lives.
Get involved today with AST's Power2Save initiative and show your support to make organ transplantation not just a treatment, but a cure!

Here are all the ways you can help:

SHARE:

We want to hear your story! Go online and record a video to share how you are connected to transplant and why others should get involved. With your help, we can inspire others!

FUNDRAISE:

Interested in supporting transplant research at a local level? Start a peer-to-peer fundraiser in lieu of birthday gifts or in honor of a loved one. It's easy! Just visit www.power2save.org/get-involved to set up your personal fundraising page, and then invite your friends and family to view it. Any money donated will help transplant recipients live their dream of a full life.

FOLLOW:

Join others in raising awareness on Facebook and Twitter or register to get updates on our progress. We need your help to spread the word about the importance of transplantation research. You have the Power2Save! For more information, visit www.power2save.org/get-involved



AMERICAN SOCIETY OF
TRANSPLANTATION



AST CEOT SUPPORTERS

At the time of printing

**THIS EDUCATIONAL ACTIVITY IS MADE POSSIBLE WITH EDUCATIONAL
GRANTS & SUPPORT FROM THE FOLLOWING COMPANIES:**



Hansa Medical



SUPPORTERS AND EXHIBITORS INFORMATION

ASTELLAS PHARMA US, INC.

Astellas Pharma US, Inc., located in Northbrook, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at www.Astellas.us.

CAREDX

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnosis. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

CEDARS-SINAI HEART INSTITUTE

The Cedars-Sinai Heart Institute is home to a distinguished team of experts who are setting the bar for cardiac care in the United States. The Heart Institute unites 16 centers and programs to diagnose and treat the full spectrum of heart conditions for all patients, from infants to those with advanced disease.

Compassionate care is integrated with an agile research enterprise, giving patients access to pioneering treatments. Led by Eduardo Marbán, MD, PhD, our faculty and attending physicians provide deep expertise across all specialties, including transplantation, stem cell therapy, congenital heart disease, women's heart health, valve disorders, arrhythmia and hypertension.

HANSA MEDICAL

Hansa Medical is a biopharmaceutical company based in Sweden, developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product is currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs.

NOVARTIS PHARMACEUTICALS CORPORATION

Novartis Pharmaceuticals Corporation has been committed to the field of transplantation for more than 30 years. With the broadest portfolio of transplant medicines in the industry, we remain dedicated to the transplant community through our research and innovation. From the exploration of new pathways and molecules to continued clinical trial investment, patients are at the center of all we do. We are proud to collaborate with leading professional and advocacy organizations in the transplant community to raise awareness of critical unmet needs in transplantation. Through a number of novel educational and awareness-raising initiatives, we are focused on expanding patients' access to life-saving organ transplants.

ONE LAMBDA

One Lambda, Inc., a Thermo Fisher Scientific brand, is a global leader in transplant diagnostics offering a full range of HLA Typing and antibody monitoring products to support clinicians and laboratories in the management of transplant patients. Visit www.onelambda.com to discover how we can help you improve patient outcomes.

SANOFI GENZYME

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

SHIRE

Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. Our 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest.

At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

VELOXIS PHARMACEUTICALS

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

VITAERISBIO

Founded in 2016, Vitaeris is a clinical-stage biopharmaceutical company based focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic Antibody Mediated Rejection (cAMR). Clazakizumab is a best-in-class IL-6 antagonist that has been studied in clinical trials involving over one thousand patients worldwide outside the transplant setting. A phase 3 clinical study for cAMR is proposed to start in 2018. More at vitaerisbio.com



OVER
30
YEARS

OF WORKING TOGETHER TO
HELP ADDRESS
PATIENT NEEDS

The logo for the American Society of Transplantation (AST) features the letters 'AST' in a bold, white, sans-serif font.

AMERICAN SOCIETY OF
TRANSPLANTATION



CUTTING EDGE of
TRANSPLANTATION



**TRANSPLANT
SUMMIT 2019**

SAVE THE DATE
FEBRUARY 21-23, 2019

ARIZONA BILTMORE | PHOENIX, AZ



Proud sponsor of CEOT 2018

ASTELLAS CARES™
TRANSPLANT



**COMMITTED TO ADVANCING
TRANSPLANTATION FOR
MORE THAN 20 YEARS**



AMERICAN SOCIETY OF
TRANSPLANTATION



FELLOWS

s y m p o s i u m

ON TRANSPLANTATION

◆◆ 2018 ◆◆

SAVE THE DATE

SEPTEMBER 28 – 30, 2018

Hilton DFW Lakes Executive Conference Center • Grapevine, TX

myAST.org

YOUNG INNOVATOR AWARD WINNERS

OSWALDO AGUIRRE

**Medstar Georgetown
University Hospital**
Washington, DC

KATHERINE ROSS

Emory University
Atlanta, GA

ALI AHMADI

**The Johns Hopkins University
School of Medicine**
Baltimore, MD

VASISHTA TATAPUDI

New York University Medical Center
New York, NY

MADONNA RICA ANGELIA

Chang Gung Memorial Hospital
Linkou, Taiwan

ARPITA BASU

Mayo Clinic
Rochester, MN

NATALIE BATH

University of Wisconsin
Madison, WI

JOSEPH LADOWSKI

University of Alabama-Birmingham
Birmingham, AL

TAYLOR MELANSON

Emory University
Atlanta, GA





POSTER ABSTRACTS

ABSTRACT# YIA1**Depletion Resistant Memory T Cells Mediate Thymoglobulin Refractory Intestinal Allograft Rejection**

Authors: Brenna Houlihan, MD¹, Abdullah Karabala, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Alexander Kroemer, MD, PhD¹, Thomas Fishbein, MD¹, Oswaldo Aguirre, MD¹

Institutions (ALL): 1. Medstar Georgetown University Hospital

ABSTRACT# YIA2**Treatment with AMD3100 and Low Dose FK506 Mitigates IRI Induced Severe Acute Kidney Injury**

Authors: Wei Wang, Le Qi, Jinny Huang, BS, Aravind Krishnan, James Burdick, Andrew Cameron, MD, George Williams, Zhaoli Sun, Ali Ahmadi, BSc¹

Institutions (ALL): 1. The Johns Hopkins University School of Medicine

ABSTRACT# YIA3**Role of Tregs in Tolerance Induction in Mouse Vascularized Osteomyocutaneous Allotransplantation**

Authors: Huang-Yu Yang¹, Hui-Yun Cheng¹, Wen-Yu Chuang¹, Fu-Chan Wei¹, Gerald Brandacher², Cheng-Hung Lin¹, Madonna Rica Anggelia, PhD Candidate³

Institutions (ALL): 1. Chang Gung Memorial Hospital
2. Johns Hopkins University
3. Chang Gung Memorial Hospital and Chang Gung University

ABSTRACT# YIA4**The Advantage of Utilizing ABO and HLA Compatible Pairs in Kidney Paired Donation**

Authors: Carrie Schinstock, MD¹, Hasan Khamash, MD², Catherine Kosberg, RN, CCTC¹, Martin Mai, MD³, Mikel Prieto, MD¹, Arpita Basu, MD, MPH⁴

Institutions (ALL): 1. Mayo Clinic, Rochester
2. Mayo Clinic, Arizona
3. Mayo Clinic, Florida
4. Mayo Clinic

ABSTRACT# YIA5**BLyS Deficient Rats Prevent Donor Specific Antibody Production and Proliferation in Rodent Model**

Authors: Bret Verhoven, BS¹, Nancy Wilson, PhD¹, Shannon Reese, MS¹, Sarah Panzer, MD¹, Robert Redfield, MD¹, Natalie Bath, MD¹

Institutions (ALL): 1. University of Wisconsin

ABSTRACT# YIA6**Genetically Engineering Kidneys for the Highly Sensitized**

Authors: Gregory Martens, MD¹, Luz Reyes, MSc, PhD¹, Zheng-Yu Wang, MD, PhD¹, Matthew Tector¹, Alfred Tector, MD, PhD, FACS¹, Joseph Ladowski, MS¹

Institutions (ALL): 1. University of Alabama-Birmingham

ABSTRACT# YIA7**Variation in Living Donor Kidney Transplantation Among U.S. Transplant Centers**

Authors: Katie Ross, MPH, Laura Plantinga, Sumit Mohan, Stephen Pastan, MD, Mohua Basu, MPH, Rachel Patzer, PhD, Taylor Melanson, BA¹

Institutions (ALL): 1. Emory University

ABSTRACT# YIA8**Racial Disparities in Post-Liver Transplant Survival Before and After Share 35 Implementation**

Authors: Raymond Lynch, MD¹, Rachel Patzer, PhD¹, Katherine Ross, MPH²

Institutions (ALL): 1. Emory Transplant Center
2. Emory University

ABSTRACT# YIA9**A2/A2B to B Renal Transplantation: Outcomes Since Implementation of New Kidney Allocation System**

Authors: Elijah Min, Nicole Ali, MD, Bruce Gelb, MD, Nabil Dagher, MD, Judith Benstein, Bonnie Lonze, MD PHD, Vasishta Tatapudi, MD¹

Institutions (ALL): 1. New York University Medical Center

ABSTRACT# A10**Frailty Assessment Pilot Study In Older Kidney Transplant Recipients**

Authors: Bethany Hale-Durbin, RN, BSN, CPTC, CCTC¹, Christine Lee, RN¹, Joanna Schaenman, MD, PhD¹, Gabriel Danovitch, MD¹, Basmah Abdalla, MD¹

Institutions (ALL): 1. University of California, Los Angeles

ABSTRACT# A11**Pre-Admissions, Resource Utilization and Survival After Kidney-Pancreas Transplantation**

Authors: Rebecca Zhang, MS¹, Ronald Parsons, MD², Andrew Adams, MD, PhD², Rachel Patzer, PhD¹, Raymond Lynch, MD², Douglas Anderson, MD¹

Institutions (ALL): 1. Emory University
2. Surgery

ABSTRACT# A12**Successful Treatment of HCV Infection with Direct Acting Antivirals after Renal Transplantation**

Authors: Atsushi Nakamura, MD, Izumi Haga, Tetsuro Takayama, Noritoshi Amada, Naoki Kawagishi, MD¹

Institutions (ALL): 1. JCHO Sendai Hospital

ABSTRACT# A13**Retrospective Analysis Of Occult Cardiac Disease In Kidney Transplant Candidates**

Authors: Sharon Klarman, RN

Institutions (ALL): Yale

ABSTRACT# A14**CMV Seromatching and Effect on Waiting Times**

Authors: Jesse Schold, PhD, M Stat, MEd¹, Ali Olyaei², Brent Gardner², Douglas Norman, MD², Joe Lockridge, MD²

Institutions (ALL): 1. Cleveland Clinic
2. Oregon Health and Sciences University

ABSTRACT# A15**Morphometric and Metabolic Correlates of Frailty in Pancreas Transplant Recipients**

Authors: Jakub Woloszyn¹, Ronald Parsons, MD¹, Raymond Lynch, MD¹

Institutions (ALL): 1. Emory Transplant Center

ABSTRACT# A16**Renal Transplant Recipients with History of Malignant Melanoma, and Post-Transplant Outcomes.**

Authors: Erik Lum, Shaker Qaqish, MBBS¹

Institutions (ALL): 1. University of California, Los Angeles

ABSTRACT# A17**Increased Successful Transplants in Sensitized Patients Using a New IgG Subtype Assay**

Authors: Dayanand Deo, PhD, Prakash Rao, PhD, MBA, FACHE, HCLD¹

Institutions (ALL): 1. New Jersey Sharing Network

ABSTRACT# A18**Histogenomics: Molecular Profiling of Kidney Biopsies Predict Delayed Graft Function**

Authors: Dayanand Deo, PhD, Prakash Rao, PhD, MBA, FACHE, HCLD¹

Institutions (ALL): 1. New Jersey Sharing Network

ABSTRACT# A19**Impact of Antiviral Therapy for HCV on Rejection and DSA Formation in Kidney Transplant Recipients.**

Authors: Ziad Zaky, MD

Institutions (ALL): Cleveland Clinic

ABSTRACT# A20**Associated Risk for Weight Gain Post-Kidney Transplantation with A New Criteria for Hypertension**

Authors: Ekamol Tantisattamo, MD¹, Praveen Ratanasrimetha, MD², Possawat Vutthikraivit, MD³, Raghavesh Pullalarevu, MD¹

Institutions (ALL): 1. Department of Internal Medicine, William Beaumont Hospital, Oakland University William Beaumont School of Medicine
2. Texas Tech University Health Sciences Center
3. Phramongkutklao College of Medicine, Mahidol University

ABSTRACT# B21**Assessing Response to Desensitization: What Makes Sense?**

Authors: Evan Kransdorf, MD, PhD¹, Jignesh Patel, MD, PhD¹, Xiaohai Zhang, PhD¹, Marcelo Pando, PhD², Michelle Kittleson, MD, PhD¹, Lawrence Czer, MD¹, David Chang, MD¹, Sadia Dimbil, BS¹, Ryan Levine, BS¹, Kristine Norland, RN¹, Michele Hamilton, MD¹, Joshua Chung, MD¹, Jon Kobashigawa, MD¹, Jaime Moriguchi, MD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute
2. Baylor Scott and White Health

ABSTRACT# B22**Pre-Transplant Memory Patients are at Rejection Risk in the First-Year after Heart Transplantation**

Authors: Sadia Dimbil, BS¹, Jignesh Patel, MD, PhD¹, Evan Kransdorf, MD, PhD¹, Ryan Levine, BS¹, Lawrence Czer, MD¹, Jon Kobashigawa, MD¹, Jaime Moriguchi, MD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B23**Donor-Derived Cell Free DNA May Detect Antibody-Mediated Rejection After Heart Transplantation**

Authors: Michelle Kittleson, MD, PhD¹, Lawrence Czer, MD¹, David Chang, MD¹, Evan Kransdorf, MD, PhD¹, Sean Sana, MD¹, James Yee, MD, PhD², Robert Woodward, PhD², Ryan Levine, BS¹, Sadia Dimbil, BS¹, Daniel Luthringer, MD¹, Jon Kobashigawa, MD¹, Jignesh Patel, MD, PhD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute
2. CareDx

ABSTRACT# B24**Long-Term Outcome of Photopheresis in Heart-Transplantation: Is It Worth It?**

Authors: Evan Kransdorf, MD, PhD¹, Sadia Dimbil, BS¹, Ryan Levine, BS¹, Lawrence Czer, MD¹, Jaime Moriguchi, MD¹, Jon Kobashigawa, MD¹, Jignesh Patel, MD, PhD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B25**Waiting for the Optimal Donor for MCS Patients Awaiting Heart Transplant**

Authors: Jaime Moriguchi, MD¹, Francisco Arabía, MD¹, Jignesh Patel, MD, PhD¹, Evan Kransdorf, MD, PhD¹, Sadia Dimbil, BS¹, Elizabeth Passano, MS¹, Lawrence Czer, MD¹, Jon Kobashigawa, MD¹, Ryan Levine, BS¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B26**Heart Transplant Across Low or Moderate Level Donor-Specific Antibodies Have Acceptable Outcome**

Authors: Jignesh Patel, MD, PhD¹, Evan Kransdorf, MD, PhD¹, Sadia Dimbil, BS¹, Lawrence Czer, MD¹, Jaime Moriguchi, MD¹, Jon Kobashigawa, MD¹, Ryan Levine, BS¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B27**Left Ventricular Assist Devices: Differences Based On Socioeconomic Status**

Authors: Omar Sadiq, MD, Celeste Williams, MD, Lindsey Aurora, MD¹

Institutions (ALL): 1. Henry Ford Hospital

ABSTRACT# B28**Gene Expression Profile Testing Scores Are Associated with New Onset Coronary Allograft Vasculopathy**

Authors: Anu Lala, Sean Pinney, MD, Robert Woodward, PhD, David Hiller, PhD, Preethi Pirlamarla, MD¹

Institutions (ALL): 1. Mount Sinai Hospital

ABSTRACT# B29**Liver Biopsy Fibrosis Not Liver Imaging Predicts Survival After Heart Transplant**

Authors: Evan Kransdorf, MD, PhD¹, David Chang, MD¹, Ken Nguyen, MD², Tram Tran, MD¹, Jignesh Patel, MD, PhD¹, Ryan Levine, BS¹, Sadia Dimbil, BS¹, Jaime Moriguchi, MD¹, Jon Kobashigawa, MD¹, Lawrence Czer, MD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute
2. University of Texas Southwestern

ABSTRACT# B30**Characterization of Vasoplegia Immediately After Heart Transplantation**

Authors: Sadia Dimbil, BS¹, Jignesh Patel, MD, PhD¹, Evan Kransdorf, MD, PhD¹, Ryan Levine, BS¹, Joshua Chan, MD¹, Fardad Esmailian,¹ Jaime Moriguchi, MD¹, Jon Kobashigawa, MD¹, Lawrence Czer, MD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B31**Outcome of Treated Sensitized MCS Patients After Heart Transplantation**

Authors: Sadia Dimbil, BS¹, Jaime Moriguchi, MD¹, Jignesh Patel, MD, PhD¹, Evan Kransdorf, MD, PhD¹, Ryan Levine, BS¹, Elizabeth Passano, MS¹, Lawrence Czer, MD¹, Jon Kobashigawa, MD¹, Francisco Arabía, MD¹

Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# C32**A Novel Technique For Monitoring Extravascular Lung Water In Donor Lungs.**

Authors: Toshihiro Okamoto, MD, PhD¹, Hiromichi Niikawa, MD, PhD¹, Yoshifumi Itoda, MD, PhD¹, Siddharth Dugar, MD¹, Samir Latifi, MD¹, Ajit Moghekar, MD¹, Kenneth McCurry, MD¹, Kamal Ayyat,¹

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C33**Positive End-Expiratory Pressure Titration In Ex-Vivo Lung Perfusion**

Authors: Toshihiro Okamoto, MD, PhD¹, Hiromichi Niikawa, MD, PhD¹, Yoshifumi Itoda, MD, PhD¹, Kenneth McCurry, MD¹, Kamal Ayyat,¹

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C34**Hyperinflation Can Predict Deterioration of Smoker's Lung Function in Ex Vivo Lung Perfusion**

Authors: Toshihiro Okamoto, MD, PhD¹, Hiromichi Niikawa, MD, PhD¹, Kamal Ayyat,¹ Carol Farver, MD¹, Kenneth McCurry, MD¹, Yoshifumi Itoda, MD, PhD¹

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C35**The Importance of Duration of Ex Vivo Lung Perfusion for Marginal Donor Lungs**

Authors: Toshihiro Okamoto, MD, PhD, Hiromichi Niikawa, MD, PhD¹

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C36**Transplant Suitability of Rejected Human Donor Lungs in Two Ex Vivo Lung Perfusion Systems**

Authors: Kenneth McCurry, MD¹, Toshihiro Okamoto, MD, PhD¹

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C37**Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart and Lung Transplantation**

Authors: Preben Brandenhoff, MD¹, Hassan Tetteh, MD²

Institutions (ALL): 1. University of Copenhagen
2. Uniformed Services University of Health Sciences

ABSTRACT# C38**AMD3100 As A Single-Dose Stem Cell Mobilizing Agent In VCA Transplantation In A Canine Model**

Authors: Scott Graves, PhD¹, Rainer Storb, MD¹, David Mathes, MD², Bruce Swearingen, MD²

Institutions (ALL): 1. Fred Hutchinson Cancer Research Center
2. University of Colorado School of Medicine

ABSTRACT# D39**IgA Recurrence in a Single Center with a Protocol Biopsy Program**

Authors: Hatem Amer, MD, Nicola Lepori, Fernando Cosio, Fernando Fervenza, Mireille El Ters, Massini Merzkani, MD¹

Institutions (ALL): 1. Mayo Clinic

ABSTRACT# D40**Incorporating Geographic Catchment Areas in Kidney Transplant Center Measures of Transplant Rates**

Authors: LaMont Sutton, MPH¹, Raymond Lynch, MD², Rachel Patzer, PhD², Katherine Ross, MPH¹

Institutions (ALL): 1. Emory University
2. Emory Transplant Center

ABSTRACT# D41**Novel Performance Metric to Improve Referral Rate for Kidney Transplants**

Authors: Gideon Aweh, MS¹, Vlad Ladik,¹ Pam Haverman,¹ Robert Taylor, MD¹, Doug Johnson, MD¹, Eduardo Lacson, MD²

Institutions (ALL): 1. Dialysis Clinic, Inc.
2. Tufts University School of Medicine

ABSTRACT# D42**Innovation in Community-Based Transplant Mentorship Program: Overcoming Barriers to Living Donation**

Authors: Anastasia Henry, BA

Institutions (ALL): American Transplant Foundation

ABSTRACT# D43**Cost Effectiveness of Lifelong Medicare Immunosuppressant Coverage for Kidney Transplant Recipients**

Authors: John Gill, MD, MS¹, Jagbir Gill¹, Scott Klarenbach², Matthew Kadatz, MD¹

Institutions (ALL): 1. University of British Columbia
2. University of Alberta

ABSTRACT# D44**Racial Differences in Medical Mistrust and Initiating Kidney Transplant Evaluation**

Authors: Jennifer Gander, Reem Hamoda, Laura McPherson, Erica Hartmann, MD, Laura Mulloy, Carlos Zayas, MD, Stephen Pastan, MD, Rachel Patzer, PhD, Kristie Lipford, PhD¹

Institutions (ALL): 1. Emory University

ABSTRACT# D45**The US Experience of Octogenarian Donor Kidney Transplantation from Analysis of UNOS/OPTN Registry**

Authors: Zheng Zhu¹, Silvi Shah¹, Masaaki Yamada, MD¹

Institutions (ALL): 1. University of Cincinnati

ABSTRACT# D46

Lines in the Sand: Navigating Existing Laws to Facilitate VCA and Organ Recovery

Authors: Helen Irving, RN MBA¹, Eduardo Rodriguez, MD DDS², Bruce Gelb, MD²

Institutions (ALL): 1. LiveOnNY
2. NYU Langone

ABSTRACT# D47

Impact Of PHS/OPTN High Risk Donors on The Waiting Time

Authors: Kelley Kulikowski, BSN, RN-BC¹, Ekamol Tantisattamo, MD¹, Danny Hollerud¹, Damanpreet Bedi, MD¹, Steven Cohn¹, Alan Koffron¹, Dilip Samarapungavan¹, Raghavesh Pullalarevu, MD¹

Institutions (ALL): 1. William Beaumont Hospital, Royal Oak, MI

ABSTRACT# E48

Bortezomib Without Plasmapheresis Is Non-Inferior to Bortezomib With Plasmapheresis

Authors: Megan Kamath, MD

Institutions (ALL): University of California, Los Angeles

ABSTRACT# E49

The Role of Donor Selection on CMV Outcomes in Small Intestinal/ Multivisceral Transplant Recipients

Authors: Harkiran Grewal, MD¹, Cal Matsumoto, MD¹, Madhuri Natarajan, MPH¹, J. Hunter Fraker, BS, BA¹, Wei Fan, MD¹, Joseph Timpone, MD¹, Mary Czech, MD¹

Institutions (ALL): 1. MedStar Georgetown University Hospital

ABSTRACT# E50

Accepting Hepatitis C-Infected Organs – The Stanford Experience

Authors: Kiran Khush, MD, MAS¹, Aliya Gulamhusein, MD, MPH², Yasbanoo Moayed, MD¹

Institutions (ALL): 1. Stanford University
2. University of Toronto

ABSTRACT# E51

Immunomonitoring Of Operational Tolerance In Intestinal Transplantation

Authors: Brenna Houlihan, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Thomas Fishbein, MD¹, Alexander Kroemer, MD, PhD¹, Oswaldo Aguirre, MD¹

Institutions (ALL): 1. Medstar Georgetown University Hospital

ABSTRACT# E52

CD8+ Tissue Resident Memory T Cells Are Key Effectors In Intestinal Transplant Patients With GvHD

Authors: Brenna Houlihan, MD¹, Abdullah Karabala, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Thomas Fishbein, MD¹, Alexander Kroemer, MD, PhD¹, Oswaldo Aguirre, MD¹

Institutions (ALL): 1. Medstar Georgetown University Hospital

ABSTRACT# E53

Organ-Specific Differences in a Belatacept-Based Protocol for Tolerance Induction in NHP

Authors: Wiebke Sommer, MD¹, Jane O, Kyu Ha Huh, Kortney Robinson, MD, Abbas Dehnadi, DVM, Isabel Hanekamp, Ivy Rosales, MD, Kurt Pruner, Josh Paster,, Rex Smith,, Robert Colvin,, Tatsuo Kawai, MD PHD, Gilles Benichou, PhD, Joren Madsen, MD, DPhil, James Allan

Institutions (ALL): 1. Massachusetts General Hospital



This image shows a full page of blank, lined paper. It features approximately 20 horizontal blue lines spaced evenly across the page, typical of notebook or composition paper. The lines are thin and light blue, set against a plain white background. There is no handwriting, printed text, or other markings on the page.

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

[illegible]

[illegible]

[illegible]

This image shows a full page of blank, lined paper. It features approximately 20 horizontal blue lines spaced evenly across the page, typical of notebook paper. The lines are thin and light blue, set against a plain white background. There is no handwriting or other markings on the page.

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Hansa Medical

Please visit our booth at the
AST's CEOt 2018 meeting
HansaMedical.com





Better Surveillance
for Better Outcomes
www.allosure.com

**AVAILABLE NOW AND FULLY
COVERED BY MEDICARE**



The Latest Innovation in Kidney Transplant Surveillance

AlloSure is the first and only, clinically and analytically validated, non-invasive test that assesses organ health by directly measuring allograft injury.

AlloSure is a blood test that measures donor-derived cell-free DNA and can accurately determine active rejection, enabling better management of your kidney transplant patients.

To learn more, please join us for a lunch symposium*:

Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients

Friday, February 9, 2018 in Frank Lloyd Wright Salon EF at 12:15 pm

*This is not an official function of the CEoT Meeting and is not endorsed by AST

Contact Us: 1-888-255-6627 | customercare@caredx.com



© 2018 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

LK-10426 Revision 1 Effective 2018-01